Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority Trial (FOSFOLD)
Fosfomycine trométamol comparé à un Autre Traitement Antibiotique Actif en Relais Pour le Traitement Des pyélonéphrites aiguës à Escherichia Coli Chez Les Femmes âgées : Essai randomisé, Multicentrique de Non infériorité
Acute pyelonephritis (APN) is among the most common bacterial infections in older women. Oral step-down antibiotic therapy may potentially be associated with toxicity, particularly with fluoroquinolones or trimethoprim-sulfamethoxazole, espcially in geriatric patients. The emergence of resistant strains reduces the choice of oral step-down treatment, thereby increasing the risk of nosocomial complications related to intravenous access and prolonged hospitalization.
Fosfomycin trometamol (FT) has broad activity against Enterobacterales, including resistant strains. It has an excellent safety profile and moderate ecological impact, and has been used for several years to treat cystitis. Recent studies have demonstrated its efficacy as an oral step-down therapy for the treatment of E.coli APN in younger women. Its efficacy in a geriatric population remains to be demonstrated.
The primary objective is to demonstrate the non-inferiority, in terms of clinical cure, of FT compared with an alternative active antibiotic as step-down therapy for E. coli APN in older women.
FOSFOLD is a national, multicenter, randomised, comparative, phase 3, non-inferiority trial (1:1), open-label with two parallel treatment groups. After 3 or 4 days of appropriate empirical antibiotic therapy, women aged 75 or over with E.coli APN will be randomised to receive either 3g of FT once daily or an alternative antibiotic treatment in accordance with current french guidelines, for a total of 10 days.
The primary endpoint is clinical cure at Day 17, i.e. 10 days after completion of antibiotic therapy.
If non-inferiority of FT is confirmed, it could provide a new therapeutic approach for oral step-down therapy in the older patients with APN. Its favorable tolerability profile could help prevent common geriatric complications, such as delirium, falls and malnutrition. Ultimately, it could help prevent some of the iatrogenic functional decline associated with hospitalisation.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名：Jérôme Lambert, MD PhD
- 电话号码：+33 +33 1 42 49 97 42
- 邮箱：jerome.lambert@u-paris.fr
研究联系人备份
- 姓名：Clara Pouchelon, MD
- 电话号码：+33 +33 1 40 36 73 67
- 邮箱：clara.pouchelon@ght-gpne.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female.
- Age ≥ 75 years.
- Body temperature ≥ 38°C on at least once during the 72 hours preceding diagnosis.
- At least one new symptom among the following : urinary urgency, dysuria, increased urinary frequency, gross hematuria, burning on urination, spontaneous of provoked flank or suprapubic pain or urinary incontinence.
- Positive urine culture collected before initiation of antibiotic therapy defined as : ≥ 10,000 leukocytes/mL and monomicrobial culture with Escherichia coli ≥ 103 CFU/mL and susceptibility to FT,the empirical antibiotic,and at least one alternative antibiotic (active and not contraindicated), administered either orally (fluoroquinolone, amoxicillin, amoxicillin-clavulanic acid, or trimethoprim-sulfamethoxazole or, in the absence of an oral alternative, intravenously.
- Ability to reveive oral medication
- Favorable clinical course after 3 or 4 days of effective empirical antibiotic therapy, defined as resolution of fever (temperature < 38°C) and regression or reduction in the intensity and/or frequency of the clinical sign(s) present at the time of APN diagnosis, without the occurrence of any new symptoms.
Exclusion Criteria:
- Presence of an infectious focus other than the urinary tract.
- Severe infection and/or initial infectious complications, including septic shock, requirement for an emergency upper urinary tract intervention, or renal abscess.
- Indwelling urinary catheter, including bladder, ureteral, or nephrostomy catheters.
- Inability to take oral medication.
- Immunosuppression, including sold-organ transplant, ongoing immunosuppressive therapy, ongoing chemotherapy.
- Hypersensitivity to fosfomycin trometamol or to any of the excipients of the study medication
- End-stage chronic kidney disease with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2.
- Lack of health insurance coverage.
- Patient under legal protection or guardianship.
- Absence of written informed consent from the patient or, if the patient is unable to provide consent, absence of agreement from the designated trusted person or a close relative.
- Participation in another interventional clinical research protocole
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Fosfomycin-trometamol (FT)
|
One sachet (3g), once daily, orally for 6 or 7 days, following 4 or 3 days, respectivelly of effective antibiotic therapy, for a total of 10 days of effective antibiotic treatment. |
|
有源比较器：Alternative antibiotic treatment
|
Treatment will be selected at the investigator's discretion, in accordance with the 2017 recommandations of the French Society for Infectious Diseases (SPILF) and the 2025 French National Authority for Health (HAS) guidelines. Therapy will be administrated for 6 or 7 days (Day 1 - Day 6/7), following 4 or 3 days, respectively of effective antibiotic therapy. The total duration of effective antibiotic therapy will be 10 days. Injection antibiotic therapy will be offered in the absence of an active oral antibiotic option. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical resolution
大体时间：Day 17
|
Clinical cure defined as :
|
Day 17
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurence of antibiotic-related adverse events
大体时间：Up to 37 days
|
Occurrence, nature, and severity of antibiotic-related adverse events, assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale. |
Up to 37 days
|
|
Occurence of geriatric complications
大体时间：Up to 37 days
|
|
Up to 37 days
|
|
Functional autonomy
大体时间：Up to 37 days
|
According to the Activities of Daily Living (ADL) scale: score ranges from 0 (complete dependence) to 6 (complete independence), with higher scores indicating greater independence in basic daily activities such as bathing, dressing, toileting, transferring and eating. |
Up to 37 days
|
|
Incidence of Infectious and urological complications
大体时间：Up to day 7
|
|
Up to day 7
|
|
Cumulative incidence of recurrent febrile or non-febrile urinary tract infectious (UTIs) (relapse or reinfection)
大体时间：From Day 17 to Day 37
|
|
From Day 17 to Day 37
|
|
Rate of hospitalization or rehospitalization following treatment for APN
大体时间：Up to day 37
|
Up to day 37
|
|
|
Length of hospital stay following randomization
大体时间：Up to day 37
|
Up to day 37
|
|
|
All-cause mortality
大体时间：Up to day 37
|
Up to day 37
|
|
|
Rate of rectal colonization with antibiotic-resistant Enterobacterales
大体时间：Up to day 37
|
fluoroquinolones, trimethoprim-sulfamethoxazole, fosfomycin, and third-generation cephalosporins |
Up to day 37
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- APHP240802
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.